TABLE 3.
Efficacy of docetaxel-loaded polymers or BCNU-loaded polymers used alone (monotherapy) or in combination
| Groups | Median survival (days) | Range (days) | Long-term survivors | P-valueb |
|---|---|---|---|---|
| Placebo polymers (control) (n = 12) | 22.5 | 18–33 | 0% | -- |
| 3.8% BCNU alone (n = 15) | 39.3 | 21–120 | 13.33% | 0.04 vs. control |
| 5% docetaxel alone (n = 15) | 39.1 | 18–120 | 6.67% | 0.01 vs. control |
| Combination of 5% docetaxel and 3.8% BCNU (n = 14) | 54.9 | 18–120 | 28.6% | 0.003 vs. control
0.14 vs. 5% docetaxel 0.18 vs. 3.8% BCNU |
a
BCNU, carmustine
b
Based on nonparametric Kruskal-Wallis statistical analyses